… number of Korean pharmaceutical and biotech companies are set to … olaparib and XAV939 in preclinical trials. With U.S. FDA Orphan Drug … the company expects the trial to finish enrollment soon … mutant cancers, ID11916 for treatment-resistant prostate cancer, and …

… researchers develop new anti-cancer drugs.  "RAD52 is a … Biology, Carver College of Medicine, University of Iowa Health … with the PARP inhibitor olaparib remain disease free for … Spies, PhD, professor of drug discovery and experimental therapeutics in …

… the Food and Drug Administration (FDA) after securing Priority … Professor of Medicine, Director of Genitourinary Medical Oncology, The … phase III trial evaluating perioperative Imfinzi as treatment for patients … followed by Lynparza (olaparib) and Imfinzi is …

… FDA-approved PARP inhibitors for ovarian cancer include olaparib … and potential for personalized medicine. By attaching specific … Other Drugs in Ovarian Cancer Treatment Anticancer Drugs in … bacterial functions fuels diverse biotechnologies. Front Cell Infect …

… when the experimental drug does harm, trials are stopped early … inhibitors in this setting, olaparib and niraparib, both of … in the Department of Medicine at Brigham and Women… financial toxicities of cancer treatment, clinical trial methods, and supportive …

… abiraterone acetate), Lynparza (olaparib) or Pluvicto (177Lu … serious underlying medical, psychiatric, psychological, familial … treatment-related complications are also excluded. More Study Details and Drug … information on the trial, use the trial ID, NCT06785636, …

… (choriocarcinoma) treated with pembrolizumab and olaparib based on high programmed death … weeks after starting pembrolizumab and olaparib, b-hCG increased steadily … targeted treatment possibilities might present a helpful step toward precision medicine in …

… MD, University of Pittsburgh Medical Center Hillman Cancer Center … of antibody-drug conjugates (ADCs), biomarker-driven treatment selection, … evaluating pembrolizumab (Keytruda) plus olaparib (Lynparza) in advanced … and Risk Reduction Trials Are of Increasing …

In the phase 3 PROpel trial (NCT03732820) patients with metastatic … combination of olaparib plus abiraterone as an important first-line treatment for … School of Medicine, Sagamihara, Kanagawa, Japan., Saitama Medical Center, Saitama Medical University, …

… Chief Medical Officer. "Our precision medicine approach … with abiraterone acetate, olaparib or 177Lu-PSMA-617 … treatments. About Pathos AI Pathos is a clinical-stage biotechnology … 2 clinical trials. Through partnerships with pharmaceutical companies, …